WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205954
Description: CBT is a MDR modulator, is also a naturally-occurring, orally bioavailable bisbenzylisoquinoline plant alkaloid with potential chemosensitization activity. MDR modulator CBT-1 binds to and inhibits the MDR efflux pump P-glycoprotein (P-gp), which may inhibit the efflux of various chemotherapeutic agents from tumor cells and reverse P-gp-mediated tumor cell MDR. P-gp is a transmembrane ATP-binding cassette (ABC) transporter and is overexpressed by some multidrug resistant tumors.
MedKoo Cat#: 205954
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
IUPAC/Chemical Name: NONE
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Meher AH, Shrivastav SS, Vibhute PJ, Hazarey PV. Deflection and stress distribution around mini-screw implants: a finite element investigation into the effect of cortical bone thickness, force magnitude and direction. J Orthod. 2012 Dec;39(4):249-55. doi: 10.1179/1465312512Z.00000000037. PubMed PMID: 23269688.
2: Kelly RJ, Robey RW, Chen CC, Draper D, Luchenko V, Barnett D, Oldham RK, Caluag Z, Frye AR, Steinberg SM, Fojo T, Bates SE. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1Â® in combination with paclitaxel in solid tumors. Oncologist. 2012;17(4):512. doi: 10.1634/theoncologist.2012-0080. Epub 2012 Mar 13. PubMed PMID: 22416063; PubMed Central PMCID: PMC3336838.
3: Mann E, Smith MJ, Hellier J, Balabanovic JA, Hamed H, Grunfeld EA, Hunter MS. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):309-18. doi: 10.1016/S1470-2045(11)70364-3. Epub 2012 Feb 15. PubMed PMID: 22340966; PubMed Central PMCID: PMC3314999.
4: Fernandez-Vina MA, de Lima M, Ciurea SO. Humoral HLA sensitization matters in CBT outcome. Blood. 2011 Dec 15;118(25):6482-4. doi: 10.1182/blood-2011-10-382630. PubMed PMID: 22174308.
5: Aykan U, Salcan I, Yildirim O, Ersanli D. Selective laser trabeculoplasty induced changes in the thickness of ciliary body and iris evaluated by ultrasound biomicroscopy. Graefes Arch Clin Exp Ophthalmol. 2011 Jun;249(6):887-94. doi: 10.1007/s00417-010-1572-x. Epub 2010 Nov 23. PubMed PMID: 21104268.
6: Catassi A, Paleari L, Servent D, Sessa F, Dominioni L, Ognio E, Cilli M, Vacca P, Mingari M, Gaudino G, Bertino P, Paolucci M, Calcaterra A, Cesario A, Granone P, Costa R, Ciarlo M, Alama A, Russo P. Targeting alpha7-nicotinic receptor for the treatment of pleural mesothelioma. Eur J Cancer. 2008 Oct;44(15):2296-311. doi: 10.1016/j.ejca.2008.06.045. Epub 2008 Aug 20. PubMed PMID: 18722110.
7: Tsiros MD, Sinn N, Brennan L, Coates AM, Walkley JW, Petkov J, Howe PR, Buckley JD. Cognitive behavioral therapy improves diet and body composition in overweight and obese adolescents. Am J Clin Nutr. 2008 May;87(5):1134-40. PubMed PMID: 18469231.
8: Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE. Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol. 2008 Mar 15;75(6):1302-12. doi: 10.1016/j.bcp.2007.12.001. Epub 2007 Dec 14. PubMed PMID: 18234154; PubMed Central PMCID: PMC2346578.
9: Spek V, Cuijpers P, NyklÃcek I, Smits N, Riper H, Keyzer J, Pop V. One-year follow-up results of a randomized controlled clinical trial on internet-based cognitive behavioural therapy for subthreshold depression in people over 50 years. Psychol Med. 2008 May;38(5):635-9. doi: 10.1017/S0033291707002590. Epub 2008 Jan 21. PubMed PMID: 18205965.
10: Stiles WB, Barkham M, Mellor-Clark J, Connell J. Effectiveness of cognitive-behavioural, person-centred, and psychodynamic therapies in UK primary-care routine practice: replication in a larger sample. Psychol Med. 2008 May;38(5):677-88. Epub 2007 Sep 10. PubMed PMID: 17825124.